Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 3—March 2022
Research

Plasmodium falciparum pfhrp2 and pfhrp3 Gene Deletions from Persons with Symptomatic Malaria Infection in Ethiopia, Kenya, Madagascar, and Rwanda

Eric RogierComments to Author , Jessica N. McCaffery, Doug Nace, Samaly Souza Svigel, Ashenafi Assefa, Jimee Hwang, Simon Kariuki, Aaron M. Samuels, Nelli Westercamp, Arsène Ratsimbasoa, Milijaona Randrianarivelojosia, Aline Uwimana, Venkatachalam Udhayakumar, and Eric S. Halsey
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E. Rogier, J.N. McCaffery, D. Nace, S.S. Svigel, A.M. Samuels, N. Westercamp, V. Udhayakumar); Ethiopia Public Health Institute, Addis Ababa, Ethiopia (A. Assefa); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J. Hwang, E.S. Halsey); Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya (S. Kariuki); Centers for Disease Control and Prevention, Kisumu (A.M. Samuels); Madagascar National Malaria Control Program, Antananarivo, Madagascar (A. Ratsimbasoa); Institut Pasteur de Madagascar, Antananarivo (M. Randrianarivelojosia); Université de Toliara, Toliara, Madagascar (M. Randrianarivelojosia); Rwanda Biomedical Center, Kigali, Rwanda (A. Uwimana)

Main Article

Table 1

Countries and study sites for each therapeutic efficacy study enrolling Plasmodium falciparum malaria–infected participants, 2016–2018

Country and 
study site No. specimens
at enrollment Median age (range), y Sex, 
% F
Ethiopia 147 18.0 (1–65) 32.9
Arba Minch 15 19.5 (10–54) 50.0
Pawe
 132
 18.0 (1–65)
 31.3
Kenya
Siaya
 332
 2.7 (0.5–4.9)
 48.8
Madagascar 620 7.0 (0.2–15) 47.1
Ankazomborona 168 8.3 (1.5–15) 41.7
Antsenavolo 54 6.0 (0.2–14) 53.7
Kianjavato 116 9.0 (0.3–15) 46.6
Matanga 172 5.0 (0.3–15) 48.3
Vohitromby
 110
 7.0 (1–15)
 50.9
Rwanda 218 3.3 (0.7–4.8) 50.9
Bugarama 88 3.3 (0.8–4.8) 52.3
Masaka 42 3.3 (0.8–4.0) 54.8
Rukara 88 3.1 (0.7–4.8) 46.6

Main Article

Page created: January 12, 2022
Page updated: February 21, 2022
Page reviewed: February 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external